Know Your Metastatic Risk

Patients typically want to know what the future holds

Image of a uveal melanoma

Image of a uveal melanoma

If you’ve just been diagnosed with uveal melanoma—also known as ocular melanoma, choroidal melanoma, or iris melanoma—it’s important to know that there is a test that can accurately identify your tumor type or Class. Specifically, the test determines whether you are at low or high risk of the cancer spreading even after your eye tumor has been successfully treated.

The test is called DecisionDx-UM, and it provides valuable information to help you and your doctor individualize the management of your disease. Validated in a prospective multi-center study, the test is the most accurate prognostic test available for uveal melanoma.

One of the intentions of this website is to provide the information you need to decide with your doctor whether this test is right for you.

The Benefits of Knowing Your Tumor Type

pullquote_spreadThere are immediate benefits to knowing your tumor type, including the ability for you and your doctor to clearly define the intensity of your monitoring and follow-up plans. While everyone hopes to land in the lowest risk group, most patients report that the information is extremely valuable to them, no matter the results (see Patient Profiles).

For one, doctors can know which patients require the most rigorous monitoring to catch and treat metastatic disease early. Half of all uveal melanoma patients may ultimately develop metastatic disease to the liver, which is currently incurable. The hope is that intensive monitoring may lead to early detection and treatment that could produce better outcomes for the patient.

Patients report other benefits of knowing their metastatic risk, including “peace of mind” and “ability to make plans” for themselves and their families. Studies have shown that most patients will choose to know their risk if they have the information and the opportunity is made available to them.

1Patients told surveillance "may" be modified 2Patients had to make advance payment of >$1,500 out of pocket for test and fee to cover FNAB procedure. 73% of patients declining testing cited cost as reason.

1 Patients told surveillance “may” be modified
2 Patients offered this chromosome 3 testing technique had to make advance payment of >$1,500 out of pocket for test plus amount needed to cover FNAB procedure. 73% of patients who declined this testing cited cost as reason.

Know your TYPE, Know your RISK
You’ve just been diagnosed with uveal melanoma, and it’s important to know that there is a test that can identify your tumor type—and the risk of your cancer spreading.

READ MORE
GETTING TESTED       Timing is Critical
To know your tumor type and risk, a biopsy must be taken BEFORE radiation treatment.

READ MORE
Talk to                 Your Doctor
Use this discussion guide to talk to your doctor about the genomic test to learn your tumor type, or CLASS.

DOWNLOAD PDF

Sign Up For Updates


Please leave this field empty.

Share on Facebook+1Share on Twitter

Share Your Stories

There's comfort in knowing you are not alone. If you or a loved one have experienced uveal melanoma and would like to help encourage others whose lives have been touched by this disease, please share your story with us.
Start Sharing